Revolution Medicines, Inc. CapEx decreased by 20.1% to $1.54M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 52.9%, from $3.27M to $1.54M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 25.1% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.31M | $454.00K | $1.18M | $1.89M | $2.53M | $3.53M | $2.88M | $1.76M | $1.12M | $2.54M | $2.32M | $3.17M | $2.40M | $3.52M | $1.22M | $3.27M | $7.45M | $3.35M | $1.93M | $1.54M |
| QoQ Change | — | -65.4% | +160.6% | +59.7% | +33.7% | +39.5% | -18.4% | -38.9% | -36.3% | +126.5% | -8.6% | +36.7% | -24.3% | +46.7% | -65.3% | +167.3% | +128.1% | -55.0% | -42.5% | -20.1% |
| YoY Change | — | — | — | — | +92.5% | +676.4% | +143.1% | -6.9% | -55.7% | -28.1% | -19.4% | +80.1% | +114.4% | +38.9% | -47.3% | +3.1% | +210.5% | -4.9% | +57.5% | -52.9% |